Russell Frank Company’s BioCryst Pharmaceuticals BCRX Stock Holding History

Russell Frank Company’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-70,958	Closed	-$809K	–	2984
2015 Q3	$809K	Sell	70,958 -30,938	-30%	-$413K	﹤0.01%	2292
2015 Q2	$1.52M	Buy	+101,896	New	+$1.16M	﹤0.01%	2124
2014 Q4	–	Sell	-69,518	Closed	-$680K	–	2974
2014 Q3	$680K	Hold	69,518	–	–	﹤0.01%	2241
2014 Q2	$872K	Sell	69,518 -1,910	-3%	-$18.6K	﹤0.01%	2118
2014 Q1	$581K	Buy	+71,428	New	+$762K	﹤0.01%	2323
2013 Q4	–	Sell	-95,795	Closed	-$697K	–	2811
2013 Q3	$697K	Buy	95,795 +95,453	+27,910%	+$484K	﹤0.01%	2358
2013 Q2	$1K	Buy	+342	New	+$590	﹤0.01%	3212

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Russell Frank Company's BCRX Position: Q4 2015 in Review

Russell Frank Company sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2015, closing a stake of 70,958 shares — an estimated $809K sold.

Russell Frank Company first reported a position in BCRX in Q2 2013 and held it in 7 quarters. The position peaked at $1.52M in Q2 2015. 118 funds tracked by Wall St. Rank hold BCRX as of Q4 2015.

Russell Frank Company reported no remaining BioCryst Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Russell Frank Company sold 70,958 BioCryst Pharmaceuticals shares in Q4 2015, an estimated $809K.
Russell Frank Company first reported a position in BioCryst Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Russell Frank Company's BioCryst Pharmaceuticals position peaked at $1.52M in Q2 2015.
118 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2015.

Based on Russell Frank Company's 13F filing for Q4 2015, filed 27 Jan 2016.